Genmab — Oktober 2024

lahn1

Yes innovaTV207 arm F and G respectively Tivdak+Ketruda and the same + carboplatin i 1L SCCHN

E_L

ok. i assume we'll hear about plans for a potential new Ph3 trial next week, as the goal was to start it in 2024...

lahn1

on the last investor call my impression from Jan was that he would want to go ahead in with. ph3 but pending on PFE. But Tox is very high so maybe..... as you said minutes ago reg. Profound

lahn1

Hvad sker der med Gen1046. Udskudt 12 mdr. Ny tekst siger at, The average trial duration for an individual subject will be about 74 weeks. 17,6 mdr. som vi så på ASCO. Så tror v det overraskende gode OS holder ?. Hvad siger 21 weeks treatment duration os ? fortæller et noget om median DoR ? som ikke var nået på ASCO

Solsen

We can expect new trials with ADCs from the M&A - this is hot in the sector. T-cell engager is aæso

Solsen

…also hot. I had listened to a call where the KOLs said that we have come to a plateau in treating solid cancers. ADCs and T-cell engagers was mentioned as exsamples where new progress could come.

Stroka

God morgen

ProinvestorNEWS

Genmab licenses Revitope's dual-antigen T-cell tech in $600M+ deal https://firstwordpharma.com/story/5907650

LP90

Godmorgen

E_L

Revitope press release - Revitope Enters into a License Agreement for Next-generation T Cell Engagement Technology https://www.prnewswire.com/news-releases/revitope-enters-into-a-license-agreement-for-next-generation-t-cell-engagement-technology-302290430.html?utm_source=dlvr.it&utm_medium=twitter

E_L

novartis q3-2024-earnings-call-transcript https://www.fool.com/earnings/call-transcripts/2024/10/29/novartis-ag-nvs-q3-2024-earnings-call-transcript/ Kesimpta -We're annualizing now well above $3 billion, and have the opportunity, I think, to well exceed our $4 billion peak sales guidance to date.

StockBull

EL 15.12: seems they have been working on this since 2021. Are part 1 completed and now part 2 . https://institut-curie.org/clinical-trial/gct1047-01

StockBull

8 Super Gems Found, Out of 100+ Stocks (Quality + Hyper Growth + Deep Value + High Cashflow) https://www.youtube.com/watch?v=ude3-6H8GtM

E_L

But they stopped recruiting. it is possible they'll get all the data they need to proceed with the 179 patients currently recruited, but i doubt that. But would very much like to hear that i am wrong here next week.

StockBull

It seems they haven't fully integrated the AI technology that was anticipated to streamline processes.

StockBull

Probably its only on future trials. Wonder if they can use less patients now that they use AI

StockBull

Implementeringen af AI i kliniske forsøg kan faktisk påvirke rekrutteringsstrategierne for patienter. AI-teknologier kan muligvis strømline processer, forbedre målretning af patienter eller forbedre dataanalyse, hvilket potentielt kan føre til mere effektiv rekruttering.

StockBull

Hvis AI-værktøjerne dog ikke er blevet ordentligt integreret, eller hvis der har været problemer med at målrette den rigtige patientpopulation, kan det også bidrage til lavere rekrutteringsnumre. Desuden, hvis studiekravene er blevet mere strenge på grund af AI-drevne indsigter, kan det begrænse antallet af kvalificerede deltagere. Det ville være nyttigt at se efter specifik information i de kommende opdateringer for at forstå AI's indvirkning på rekrutteringen til GEN1047.

StockBull

Welcome to Genmab

(www.genmab.com)

StockBull

Optimizing clinical trials
Clinical trials are essential for evaluating the safety and efficacy of new treatments. Yet they can be lengthy, costly and challenging. Genmab is using AI to optimize the clinical trials process, applying the technology to help identify suitable patient populations, streamline the recruitment process, and design and execute trials more efficiently.